Cure My Disease

Don't miss your cure!

 Log in / Sign up

CT-Guided heart ablation may speed up treatment for dangerous heart rhythm

NCT ID NCT05225935

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether using a CT scan before heart ablation can make the procedure faster and safer for people with ventricular tachycardia, a fast heart rhythm that can be life-threatening. 119 adults who had a prior heart attack and an implanted defibrillator were randomly assigned to standard ablation or a CT-guided approach. The main goal was to see if the CT-guided method shortened procedure time, with secondary checks on safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
catheter ablation procedure guided by CT scan imaging
What this could lead to
If successful, this approach could make heart ablation faster and more precise, reducing procedure time and possibly improving safety for patients with ventricular tachycardia.
What could go wrong
This is a completed study with 119 participants, so results are limited in size. The benefit may not apply to all patients, and there are standard risks of ablation like bleeding or heart rhythm issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

119 people

The number who actually took part.

Started

Jun 2022

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years, * Indication for catheter ablation intervention with planned preoperative cardiac CT scan * Prior myocardial infarction (using the international definition of MI: Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non- ischemic cause with documentation of prior ischemic injury), * Presence of an implantable cardioverter defibrillator, or planned ID implantation before discharge, and * One of the following monomorphic VT events within last 6 months: * A: ≥3 episodes of VT treated with antitachycardia pacing (ATP), * B: ≥1 appropriate ICD shocks, * C: sustained VT below detection rate of the ICD documented by ECG or any cardiac monitor * D: Sustained VT recorded on 12 leads ECG in the absence of ICD * Highly effective contraception for women of childbearing potential, maintained during research procedures * Signed informed consent , * Affiliated to or beneficiary of a health insurance Exclusion Criteria: * Unable to understand the nature, risks, significance and implications of the clinical investigation or unwilling to provide written informed consent, * Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days thought to be due to acute coronary arterial thrombosis, or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia, * Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves, * Have had a prior catheter ablation procedure for VT, * Presenting arrhythmia: polymorphic VT or ventricular fibrillation (VF), * Renal failure (Creatinine clearance \<30 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to \<1 year, * Women who are pregnant, lactating, or who are planning to become pregnant during the anticipated study period, * Patient under legal protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ventricular tachycardia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myocardial infarction ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ventricular tachycardia

Contacts and locations

Locations

  • APHP Salpétrière

    Paris, France

  • Asklepios Klinik St. Georg Hamburg

    Hamburg, Germany

  • CHU de Bordeaux

    Pessac, France

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, France

  • CHU de Limoges

    Limoges, France

  • CHU de Toulouse

    Toulouse, France

  • Deutsches Herzzentrum München

    München, Germany

  • Evangelisches Krankenhaus Düsseldorf

    Düsseldorf, Germany

  • Inselspital, Universitätsspital Bern

    Bern, Switzerland

  • Medical University of Graz

    Graz, Austria

  • Public Hospital Elisabethinen Linz

    Linz, Austria

  • Rhön-Klinikum AG

    Bad Neustadt an der Saale, Germany

  • Universitätsklinikum Schleswig-Holstein

    Lübeck, Schleswig-Holstein, 23538, Germany

  • Vaudois University Hospital, Lausanne

    Lausanne, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.